ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

7,542Medicare Part D Prescriptions Filled, Including Refills

Rank: 17 out of 251

$464K Total Retail Price of All Prescriptions

Rank: 24 out of 251

374 Patients Receiving at Least One Drug in Part D
79%Patients 65 Years and Older
36% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in New Hampshire
Lower avg

Schedule Two
Controlled Substances

10% of this provider’s 374 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

6% of this provider’s 374 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

1% of this provider’s 5,656 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$61 was the average price of a prescription from this provider, compared to $64 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in New Hampshire
AMLODIPINE BESYLATE 280 248 1 4
LEVOTHYROXINE SODIUM 264 217 2 3
SIMVASTATIN 254 236 3 1
HYDROCHLOROTHIAZIDE 218 211 4 9
ATORVASTATIN CALCIUM 217 197 5 8
FUROSEMIDE 175 130 6 6
CARVEDILOL 173 154 7 41
ZOLPIDEM TARTRATE 163 109 8 19
LISINOPRIL 157 124 9 2
METOPROLOL SUCCINATE 143 117 10 13
NEXIUM 118 58 11 28
ALLOPURINOL 114 101 12 34
CRESTOR 110 88 13 21
PRAVASTATIN SODIUM 108 69 14 14
PREDNISONE 106 69 15 27
SERTRALINE HCL 103 62 16 22
OMEPRAZOLE 101 94 17 5
LOSARTAN POTASSIUM 95 86 18 17
KLOR-CON M20 89 63 19 45
RANITIDINE HCL 84 79 20 35
TRAMADOL HCL 83 63 21 24
METOPROLOL TARTRATE 81 69 22 7
OXYCODONE HCL 78 34 S2 23 30
WARFARIN SODIUM 74 73 24 11
PANTOPRAZOLE SODIUM 73 57 25 20
POTASSIUM CHLORIDE 73 62 25 33
FLUTICASONE PROPIONATE 72 56 27 38
ATENOLOL 70 70 28 12
CLOPIDOGREL 65 56 29 60
PROAIR HFA 62 11 30 42
LOSARTAN-HYDROCHLOROTHIAZIDE 62 40 30 95
LOVASTATIN 62 40 30 31
LIPITOR 60 60 33 66
HYDROCODONE-ACETAMINOPHEN 60 31 S3 33 18
TRAZODONE HCL 59 50 35 26
AZITHROMYCIN 58 37 36 59
FLUOXETINE HCL 58 37 36 52
OXYCODONE-ACETAMINOPHEN 57 18 S2 38 55
DONEPEZIL HCL 57 50 38 29
METFORMIN HCL 57 41 38 10
DOXAZOSIN MESYLATE 55 48 41 97
GABAPENTIN 53 28 42 16
ADVAIR DISKUS 52 29 43 25
ISOSORBIDE MONONITRATE ER 52 49 43 78
LISINOPRIL-HYDROCHLOROTHIAZIDE 52 24 43 48
RAMIPRIL 50 40 46 161
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 28, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.